Opinion
Video
Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
Author(s):
Martin Voss, MD, discusses the subgroup analysis of the COSMIC-313 study, which investigated the combination of nivolumab, ipilimumab, with or without cabozantinib (nivo + ipi +/- cabo), focusing on the potential advantages this treatment approach may offer for patients with intermediate to high-risk renal cell carcinoma (RCC).
EP: 1.Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
EP: 2.Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
EP: 3.Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
Now Viewing
EP: 4.Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
- Briefly comment on the COSMIC-313 nivo + ipi +/- cabo study in intermediate/high-risk patients subgroup analysis (Powles, et al. ASCO GU 2023: Abstract 605)
- Dr Voss takes time to highlight the LITESPARK-024 trial = belzutifan + palbo > – (McDermott D, et al. ASCO 2023. Abstract TPS4603)
Related Videos
Related Content
